Niagen Bioscience, Inc. is classed by the SEC under Medicinal Chemicals & Botanical Products (industry code 2833), based in Los Angeles, CA. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $129 million and a profit of $17 million (its filed statements).
Product businessMedicinal Chemicals & Botanical ProductsLos Angeles, CAfilings since 20079 of 9 filed
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a product business: prior from its industry code (SEC 2833, Medicinal Chemicals & Botanical Products); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 6.8 out of ten, 9 of 9 metrics filed: past 5.6 out of ten, present 7.0 out of ten, future 7.7 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
Surviving crises (past): 5.0 out of ten. 3 warning events since 2017; the latest 2024-12-16. 50th percentile among 20 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Track record (past): 6.6 out of ten. +25.4% a year over 9 filed years; profitable in 2 of 9. 66th percentile among 18 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Shareholder treatment (past): 4.6 out of ten. Share count grew 4.3% a year. 1% of cash flow returned. Insiders: 0 sales, 2 purchases. 46th percentile among 9 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Financial health (present): 7.8 out of ten. ROE 23%: 23¢ of profit per shareholder dollar. Leverage 28%: owes 28¢ per asset dollar. 78th percentile among 20 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Industry position (present): 7.3 out of ten. top 27% of 18 in its family; net margin 13.4%. 73rd percentile among 18 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Leadership (present): 4.8 out of ten. bottom 48% of 12 in its family for leadership; chief executive since 2023. 48th percentile among 12 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
Room to expand (future): 8.5 out of ten. top 15% of 18 in its family for room to expand. 85th percentile among 18 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Growth drivers (future): 6.7 out of ten. top 33% of 18 in its family for growth drivers. 67th percentile among 18 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Expectations vs reality (future): 7.6 out of ten. top 24% of 18 in its family for expectations against reality. 76th percentile among 18 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
The filing record
Newest annual report: Form 10-K filed 2026-03-04 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-08-04 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-08-04 (on EDGAR). Newest filing: Form 10-Q, 2026-08-04. Filings on record since 2007. Read from EDGAR 2026-10-12.
Where the revenue comes from
Lines of business in fiscal 2025: Consumer Products 76%, Ingredients 22%, Analytical Reference Standards and Services 2%. As tagged in its annual report (Form 10-K, filed 2026-03-04).
Who runs it
Fried, Robert N (Chief Executive Officer); Jaksch, Frank L Jr (EXECUTIVE CHAIRMAN OF BOARD); Pamir, Ozan (Chief Financial Officer); Lopez, Carlos Luis (SVP, General Counsel); Cohen, Ann (director); Ng, Wang Yu Gary (director); Patrick, Kristin (director); Rubin, Steven D (director); Shahbazi, Hamed (director); Yu, Wing Tak Wendy (director). 10 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.